Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
Ruxolitinib and Methylprednisolone As First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Terminated
Participants recruitment failure
Other terminated trials from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A PHASE2 clinical study on Acute GVHD, this trial is terminated or withdrawn. The trial is conducted by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Nov 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .